X-37 utilizes AI-driven methodologies to identify and develop small molecules targeting difficult-to-drug proteins associated with autoimmune diseases, cancer, and anticoagulation. By focusing on high-value therapeutic targets, the company aims to accelerate the discovery of safe and effective treatments in areas traditionally resistant to conventional drug development.
Funding
$14.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DBFounders
Product
Problem
Many proteins implicated in autoimmune diseases, cancer, and anticoagulation are considered "difficult-to-drug" due to their structural properties or lack of accessible binding sites. Traditional drug discovery methods often struggle to identify small molecules that can effectively and selectively bind to these challenging targets. This limitation hinders the development of new therapies for diseases where these proteins play a critical role.
Solution
X-37 employs an AI-driven drug discovery platform to identify and develop small molecule therapeutics that target traditionally undruggable proteins. By leveraging advanced computational methods and partnerships with specialized AI companies, X-37 expands the accessible chemical space and accelerates the identification of molecules with high potency and selectivity. The company focuses on high-value therapeutic targets with established causal roles in autoimmune diseases, cancer, and anticoagulation. This approach aims to overcome the limitations of conventional drug discovery and unlock new treatment options for diseases with unmet medical needs.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and patients seeking novel therapies for autoimmune diseases, cancer, and anticoagulation.
Features
- AI-driven platform for identifying small molecules that bind to difficult-to-drug proteins.
- Focus on targets with established causal roles in autoimmune disease, cancer, and anticoagulation.
- Partnerships with AI companies specializing in cutting-edge drug discovery technology.
- Flexible approach to selecting the best technology for each target in the pipeline.
- Aims to develop safe and effective therapies in areas traditionally resistant to conventional drug development.